Literature DB >> 33969157

High prevalence of plasma EBV DNA among the HIV positive individuals, with or without malignancies, attending the clinic at AIIMS, New Delhi.

Dibyakanti Mandal1,2, Devashish Desai1, Sanjeev Sinha1.   

Abstract

Epstein-Barr Virus (EBV) is associated with the Hodgkin's and Non-Hodgkin's lymphoma (HL and NHL respectively). HIV is a risk factor for EBV infections and previously published data indicate that HIV infected individuals have higher chances of getting EBV infections compared to HIV uninfected individuals. Very limited information is available from India about the the prevalence of EBV in HIV positivity, with or without malignancy. In a recent study (Sinha et al. Current HIV Res 16:1-6, 2018) from All India Institute of Medical Sciences (AIIMS), New Delhi, we have shown that 2% among the HIV-1 infected individuals have malignancies including HL and NHL. To determine the prevalence of EBV among these individuals, clinical specimen obtained from ART clinic of AIIMS were tested for the presence of EBV DNA in plasma samples by quantitative real-time PCR. We have observed high prevalence of EBV (30%) among the 92 specimen tested. Prevalence is higher in patients with malignancy (37%) compared to those without maliganancy (27%). No correlation was observed with the CD4 counts or HIV viral load with EBV positivity. © Indian Virological Society 2021.

Entities:  

Keywords:  EBV DNA; HIV infection

Year:  2021        PMID: 33969157      PMCID: PMC8093145          DOI: 10.1007/s13337-020-00649-0

Source DB:  PubMed          Journal:  Virusdisease        ISSN: 2347-3584


  16 in total

1.  Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study.

Authors:  Nancy Crum-Cianflone; Katherine Huppler Hullsiek; Vincent Marconi; Amy Weintrob; Anuradha Ganesan; R Vincent Barthel; Susan Fraser; Brian K Agan; Scott Wegner
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177

Review 2.  Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges.

Authors:  Paul G Rubinstein; David M Aboulafia; Andrew Zloza
Journal:  AIDS       Date:  2014-02-20       Impact factor: 4.177

3.  Cancer burden in the HIV-infected population in the United States.

Authors:  Meredith S Shiels; Ruth M Pfeiffer; Mitchell H Gail; H Irene Hall; Jianmin Li; Anil K Chaturvedi; Kishor Bhatia; Thomas S Uldrick; Robert Yarchoan; James J Goedert; Eric A Engels
Journal:  J Natl Cancer Inst       Date:  2011-04-11       Impact factor: 13.506

4.  Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients.

Authors:  Maria Raffaella Petrara; Anna Maria Cattelan; Marisa Zanchetta; Lolita Sasset; Riccardo Freguja; Ketty Gianesin; Maria Grazia Cecchetto; Francesco Carmona; Anita De Rossi
Journal:  J Clin Virol       Date:  2011-12-30       Impact factor: 3.168

Review 5.  HIV-Associated Cancers and Related Diseases.

Authors:  Robert Yarchoan; Thomas S Uldrick
Journal:  N Engl J Med       Date:  2018-03-15       Impact factor: 91.245

6.  Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen.

Authors:  S J Stevens; I Pronk; J M Middeldorp
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

7.  Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy.

Authors:  Paul D Ling; Regis A Vilchez; Wendy A Keitel; David G Poston; Rong Sheng Peng; Zoe S White; Fehmida Visnegarwala; Dorothy E Lewis; Janet S Butel
Journal:  Clin Infect Dis       Date:  2003-09-23       Impact factor: 9.079

8.  The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases.

Authors:  Jennifer A Kanakry; Aparna M Hegde; Christine M Durand; Allan B Massie; Amy E Greer; Richard F Ambinder; Alexandra Valsamakis
Journal:  Blood       Date:  2016-01-07       Impact factor: 22.113

9.  A pilot trial of quantitative Epstein-Barr virus polymerase chain reaction in patients undergoing treatment for their malignancy: potential use of Epstein-Barr virus polymerase chain reaction in multiple cancer types.

Authors:  Donald E Tsai; Marlise R Luskin; Brandon E Kremer; Albert K Chung; Sharon Arnoldi; Vikram R Paralkar; Sunita D Nasta; Edward A Stadtmauer; Stephen J Schuster; Marin Xavier
Journal:  Leuk Lymphoma       Date:  2014-11-05

10.  Prevalence of HIV in Patients with Malignancy and of Malignancy in HIV Patients in a Tertiary Care Center from North India.

Authors:  Sanjeev Sinha; Ashish Agarwal; Kartik Gupta; Dibyakanti Mandal; Mitul Jain; Roger Detels; Karabi Nandy; Michelle A DeVos; S K Sharma; N Manoharan; P K Julka; G K Rath; Richard F Ambinder; Ronald T Mitsuyasu
Journal:  Curr HIV Res       Date:  2018       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.